SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently the focal point of intense market attention during an FDA Advisory Committee meeting, where investors and patient advocates are closely monitoring a pivotal debate over the efficacy of deramiocel for Duchenne muscular dystrophy. The discourse is driven by high-stakes community tension regarding the FDA's interpretation of statistical data versus real-world patient outcomes, further amplified by the timely publication of HOPE-3 trial results in The Lancet that provide a significant potential counter-narrative to FDA briefing concerns.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant selling pressure and volatility despite reporting a triple earnings beat and raising full-year guidance. The community is actively debating whether to buy the dip, with many retail investors expressing frustration over the persistent post-earnings sell-off and potential manipulation, while others view the current price as a long-term accumulation opportunity.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market sentiment surrounding SPY is dominated by the Federal Reserve's interest rate decision, with the community closely tracking whether the Fed will maintain current rates or pivot to a more hawkish stance to combat persistent inflation. Traders are actively debating the potential for a V-shaped market recovery versus a deeper correction, fueled by ongoing geopolitical tensions in the Middle East and concerns over large-cap tech earnings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing significant volatility as market participants fixate on the Federal Reserve's interest rate decision, with traders heavily debating whether a lack of rate hikes will trigger a relief rally or if underlying inflation concerns and geopolitical tensions will drive further selling. Community sentiment is deeply divided, with many actively discussing the potential for a 'V-shaped' recovery or a broader market correction driven by concerns over institutional positioning, earnings expectations, and the sustainability of AI-related sector growth.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is trending as investors aggressively hedge against market volatility and shifting interest rate expectations, with ongoing debate about whether Treasury bonds can serve as a reliable safe haven given the backdrop of elevated global debt and geopolitical instability in the Strait of Hormuz. Community members are actively discussing the possibility of a recession or market correction, specifically questioning whether the Federal Reserve's restrictive stance and rising long-term yields will trigger a larger liquidity event or a flight to safety.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing a significant sell-off driven by a 'sell the news' reaction following positive FDA advisory committee votes on peptide compounding, compounded by intensifying pressure from short sellers and broader market volatility. While investors remain divided on the long-term impact of regulatory hurdles and the potential for a massive new revenue stream, the community is actively debating whether this pullback represents an attractive buying opportunity or a deeper breakdown in sentiment.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The iShares Russell 2000 ETF is experiencing heightened volatility as investors debate the potential for future interest rate hikes against a backdrop of geopolitical tension and shifting economic indicators. The community remains divided, with some traders hedging against a deeper pullback while others look for signs of a market rotation that could sustain the current uptrend.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings Co (VRT) is seeing intense community discussion driven by its strategic role in the AI data center build-out, though shares face volatility following a recent revenue miss and ongoing valuation debates. While some investors are concerned about the stock's premium valuation and recent pullback, many are using the dip to accumulate, citing Vertiv's critical positioning in power and cooling infrastructure as AI infrastructure demand continues to scale.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is currently at the center of investor focus as markets navigate a period of high volatility driven by a major tech-sector rotation and anticipation surrounding key Federal Reserve policy updates. Community members are actively debating the sustainability of an AI-driven rally, with many traders closely monitoring liquidity flows and institutional sentiment as the market balances geopolitical uncertainty against ongoing earnings reports.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing high volatility as investors grapple with broader semiconductor sector weakness and regional market headwinds, leading to intense community debate over whether this represents a fundamental buying opportunity or a deeper cyclical downturn. While some participants are frustrated by the stock's decoupling from positive sector news and active short-selling pressure, others emphasize the company's long-term potential in AI-driven memory demand and its significant share buyback capacity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BofA y&#39;day⬆️Top Pick $ARGX to $1,088 from $1016, reitd Buy/said—Following ARGX&#39;s recent Myositis Investor Event (see our June 24 note), we add standalone value for immune-mediated necrotizing myopathy (INM) to our model. 
 
The new disclosure that the INM subgroup was the key driver of the clinically meaningful responses in phase 2 (&gt;60% of patients enrolled) and KOL feedback underscoring the high unmet need and clear biological rationale for Vyvgart in INM gives us increased confidence in the potential for a positive phase 3 readout in 3Q. 
 
We are also encouraged by INM receiving BTD and the company&#39;s alignment with regulators on the filing path. 
 
We think INM represents an attractive commercial opportunity given the lack of approved therapies and high morbidity and view it as a key entry point into rheumatology by opening the door to further expand the Vyvgart franchise. 
 
We reiterate our Buy rating with new $1,088/€955 ΡΟ. ARGX remains a top pick in 2026 as we head into a catalyst-rich 2H.

Oppenheimer⬆️the PT on $ARGX to $1040 from $778, reiterated at Outperform rating, and said: We raise our PT to $1,040 (from $778) as we revise our model to reflect higher expected Vyvgart sales in its major approved indications (gMG, CIDP) as well as to include value contribution in its expansion opportunities within myasthenia gravis (snMG, oMG). 
 
We continue to assign risk-adjusted value in Sjogren&#39;s and myositis. 
 
We have also added em-bart to our model by recognizing its eventual commercial potential in MMN. 
 
We now forecast 2026-28 total revenue of $6.5B, $8.0B, and $10.1B vs. consensus views of $5.8B, $6.9B, and $8.2B, and 2026-28 EPS of $31.10, $40.75, and $55.48 vs. Street&#39;s $28.82, $38.54, and $49.70, respectively. 
 
With shares +48% YTD (vs. $XBI +28%), we see further outperformance on development program progress-five Phase 3 readouts in 2026-atop continued commercial execution.

StockTwits Web

Argenx

SPDR S&P Biotech ETF

Quantumup

 to $1,088 from $1016, reitd Buy/said—Following ARGX's recent Myositis Investor Event (see our June 24 note), we add standalone value for immune-mediated necrotizing myopathy (INM) to our model. 
 
The new disclosure that the INM subgroup was the key driver of the clinically meaningful responses in phase 2 (>60% of patients enrolled) and KOL feedback underscoring the high unmet need and clear biological rationale for Vyvgart in INM gives us increased confidence in the potential for a positive phase 3 readout in 3Q. 
 
We are also encouraged by INM receiving BTD and the company's alignment with regulators on the filing path. 
 
We think INM represents an attractive commercial opportunity given the lack of approved therapies and high morbidity and view it as a key entry point into rheumatology by opening the door to further expand the Vyvgart franchise. 
 
We reiterate our Buy rating with new $1,088/€955 ΡΟ. ARGX remains a top pick in 2026 as we head into a catalyst-rich 2H.